Peginterferon Alfa-2a Plus Ribavirin Plus Amantadine for the Treatment of Hepatitis C Infected Patients
Status:
Completed
Trial end date:
2004-04-01
Target enrollment:
Participant gender:
Summary
Response to a second-line anti-HCV treatment in non responder patients to a first-line dual
therapy remains very poor. Preliminary studies of amantadine suggest that this drug could be
potentially effective to treat hepatitis C.